{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "SoA Reference in Amendment Summary",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA), Table 1",
        "description": "Reference in the amendment summary table to an addition to a footnote in the Schedule of Activities."
      },
      {
        "id": "ref_2",
        "name": "Screening Procedures Reference in Amendment Summary",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference in the amendment summary table to details on procedures specific to screening sites in the US."
      },
      {
        "id": "ref_3",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference from Section 2.3.1.1 to Section 10.5 for potential risks and mitigation measures due to COVID-19 vaccine."
      },
      {
        "id": "ref_4",
        "name": "Dose Modification for Potential Risks",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Multiple references in Table 3 to Section 6.6 for dose modification or discontinuation strategies for various potential risks."
      },
      {
        "id": "ref_5",
        "name": "Adaptive Features Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference in Section 4.1 to Table 4 for a description of adaptive design features."
      },
      {
        "id": "ref_6",
        "name": "Dose Modification Criteria Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference in Section 4.1 to Table 7 for criteria on when a dose should be decreased or interrupted."
      },
      {
        "id": "ref_7",
        "name": "Screening Blood Donation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference in Table 5 to Section 5.2 regarding exclusion criteria for blood donation prior to screening."
      },
      {
        "id": "ref_8",
        "name": "Contraception Methods Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference in Table 5 to Section 10.4 for description of appropriate contraceptive methods."
      },
      {
        "id": "ref_9",
        "name": "Contraception Start Time Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference in Table 5 to Section 5.1 for start times for contraceptive use."
      },
      {
        "id": "ref_10",
        "name": "Discontinuation Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference in Section 7.1 to the SoA for data to be collected at the time of study intervention discontinuation."
      },
      {
        "id": "ref_11",
        "name": "Discontinuation for Liver Function Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference in Section 7.1 to dose modification criteria for discontinuing due to abnormal liver function."
      },
      {
        "id": "ref_12",
        "name": "Discontinuation for Pregnancy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference in Section 7.1 to the pregnancy section for discontinuation criteria."
      },
      {
        "id": "ref_13",
        "name": "Discontinuation Samples Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference in Section 7.1 to the SoA (Table 1) for samples and data to be collected at study intervention discontinuation."
      },
      {
        "id": "ref_14",
        "name": "QTc Withdrawal Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
        "description": "Reference in Section 8.2.3 to Section 7 for QTc withdrawal criteria."
      },
      {
        "id": "ref_15",
        "name": "Clinical Lab Tests List Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference in Section 8.2.4 to Section 10.2 for the list of clinical laboratory tests to be performed."
      },
      {
        "id": "ref_16",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Multiple references in Section 8.3 to Section 10.3 for procedures on recording, evaluating, and reporting AEs and SAEs."
      },
      {
        "id": "ref_17",
        "name": "Lost to Follow-up Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference in Section 8.3.3 to Section 7.3 for the definition of 'lost to follow-up'."
      },
      {
        "id": "ref_18",
        "name": "Genetic Testing Non-use Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference in Section 8.3.6 stating that biobanked samples will not be used for genetic testing."
      },
      {
        "id": "ref_19",
        "name": "PK/PD/Biomarker Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference in Sections 8.5 and 8.8 to Section 8.1.1 for details of copper and molybdenum measurements."
      },
      {
        "id": "ref_20",
        "name": "Pharmacodynamics Biomarker Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference in Section 8.8 to Section 8.6 for details of PD biomarkers."
      },
      {
        "id": "ref_21",
        "name": "Analysis Populations Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference in Section 9.3 to Table 8, which defines the population sets for analysis."
      },
      {
        "id": "ref_22",
        "name": "Figure 1: Study Schematic",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 1",
        "sectionTitle": "Study Schematic",
        "description": "Listing of Figure 1 in the List of Figures."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union, the US Food and Drug Administrationâ€™s (FDA) regulation at 21 CFR part 312.30(b), and any applicable local regulations.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in participants with WD; see the IB.",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "2.3.1.1",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Limited nonclinical data on copper elimination with tetrathiomolybdate suggested copper excretion may be at least maintained or increased with repeated dosing (refer to the current IB).",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.2",
        "pageNumber": 27
      },
      {
        "id": "annot_4",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4",
        "pageNumber": 53
      },
      {
        "id": "annot_5",
        "text": "This study will be conducted in accordance with the protocol and with the following: Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines, Applicable laws and regulations.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "10.1.1",
        "pageNumber": 55
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Current protocol version. Clarifies study procedures in the US to facilitate recruitment and lessen participant inconvenience.",
        "amendmentNumber": "Amendment 3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Previous approved protocol amendment.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Previous approved protocol amendment.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Previous approved protocol amendment.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original approved protocol.",
        "amendmentNumber": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 22,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}